Fluconazole plus cyclosporine: A fungicidal combination effective against experimental due to Candida albicans

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 11, 2000, Pages 2932-2938

  Marchetti, O ^a   Entenza, J M ^a   Sanglard, D ^a   Bille, J ^a   Glauser, M P ^a   Moreillon, P ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CYCLOSPORIN; FLUCONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CELL INFILTRATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; ENDOCARDITIS; FEMALE; FUNGICIDAL ACTIVITY; FUNGUS GROWTH; HISTOPATHOLOGY; KIDNEY INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; CYCLOSPORINE; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; ENDOCARDITIS; FEMALE; FLUCONAZOLE; KIDNEY; MICROBIAL SENSITIVITY TESTS; RATS; RATS, WISTAR; TREATMENT OUTCOME;

EID: 0033751965     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.11.2932-2938.2000     Document Type: Article

References (45)

1. Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections
2. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990
3. Pharmacokinetics and tissue penetration of fluconazole in humans
4. Candida albicans endocarditis: Ultrastructural studies of vegetation formation
5. Comparison of fluconazole and amphotericin B for treatment of experimental Candida albicans endocarditis in rabbits
6. Blood levels and nephrotoxicity of cyclosporin A and G in rats
7. Controversies in the management of candidiasis in neutropenic patients treated for malignant diseases: New versus old or better versus worse
8. Synergistic antifungal activities of bafilomycin A1, fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK 506 and L-685,818 against Cryptococcus neoformans
9. Genetic separation of FK 506 susceptibility and drug transport in the yeast Pdr5 ATP-binding cassette multidrug resistance transporter
10. Amphotericin B serum concentrations during therapy
11. Isogenic strain construction and gene mapping in Candida albicans
12. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A
13. Amphotericin B: 30 Years of clinical experience
14. Synergy of fluconazole with human monocytes or monocyte-derived macrophages for killing of Candida species
15. Cyclosporin partitions into phospholipid vesicles and disrupts membrane architecture
16. Natural history of aortic valve endocarditis in rats
17. ABC transporters: From microorganisms to man
18. The mechanism of action of cyclosporin A and FK 506
19. Cyclosporin A inhibits Coccidioides immitis in vitro and in vivo
20. Comparison of immunosuppressive effects of cyclosporine A in a murine model of systemic candidiasis and of localized trushlike lesions
21. Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia
22. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes
23. Pharmacokinetic studies of fluconazole in rabbits characterizing doses which achieve peak levels in serum and area under the concentration-time curve values which mimic those of high-dose fluconazole in humans
24. Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans
25. Antifungal drugs: Mechanisms of action, drug resistance, susceptibility testing, and assays of activity in biologic fluids
26. Treatment of murine cryptococcosis with cyclosporin A in normal and athymic mice
27. The changing face of candidemia: Emergence of non-Candida albicans species and antifungal resistance
28. In vitro and in vivo antifungal activity of cyclosporine
29. Multiple drug resistance in human cancer
30. Comparison of amphotericin B and n-D-ornithyl amphotericin B methyl ester in experimental cryptococcal meningitis and Candida albicans endocarditis with pyelonephritis
31. The kidneys in systemic infections
32. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia
33. Tissue penetration of amphotericin B in Candida endocarditis
34. Combination therapy with amphotericin B and fluconazole against invasive candidiasis in neutropenic-mouse and infective-endocarditis rabbit models
35. Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors
36. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: Characterization of CDR2, a new multidrug ABC transporter gene
37. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters
38. Characterization of anti-Toxoplasma activity of SDZ 215-918, a cyclosporin derivative lacking immunosuppressive and peptidyl-prolyl-isomerase-inhibiting activity: Possible role of a P glycoprotein in Toxoplasma physiology
39. Reversal of drug-resistance by cyclosporin-A in a patient with acute myelocytic leukemia
40. Effectiveness of quinolone antibiotics in modulating the effects of antifungal drugs
41. Pharmacokinetics and tissue penetration of fluconazole in rabbits
42. Comparison of fluconazole and amphotericin B for prevention and treatment of experimental Candida endocarditis
43. Comparison of flaconazole and amphotericin B for treatment of experimental Candida endocarditis caused by non-Candida albicans strains
44. Cyclosporine: Pharmacokinetics, metabolism, and drug interactions